Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the quarter ended 30th June, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Trident Lifeline reported Q1FY26 revenue of ₹1,935.48 lakh, up 27% YoY from ₹1,520.96 lakh. EBITDA grew 20% YoY to ₹546.36 lakh, though margins moderated to 28% from 30% in Q1FY25 (down 169 bps). Profit after tax rose 15% YoY to ₹347.59 lakh, with EPS at ₹3.02. Interest costs surged 62% YoY and depreciation rose 57% YoY due to recent capacity expansion. The company highlighted a strong pipeline of 2,329 product registrations across 43 countries, with 1,035 already registered, and continues inorganic expansion through subsidiaries (TNS Pharma, Tricorp Industries, TLL Parenterals, Trident Mediquip). Management expressed confidence in growth at both standalone and consolidated levels for the year.
Strong top-line growth of 27% YoY and 20% EBITDA growth signal robust business momentum, but margin compression and sharply higher finance/depreciation costs (reflecting recent expansion) are points to monitor. Shareholders may view positively the disclosed acquisition strategy and large product registration pipeline, which underpins future revenue visibility.